… In Covid-19, high neutrophil recruitment is correlated with disease severity; thereby
colchicine may reduce Covid-19 severity through inhibition of NLRP3 inflammasome, neutrophil …

… inflammasome in the pathogenesis of COVID-19 (… inhibitors targeting the NLRP3
inflammasome, cytokine products and neutrophils to provide novel therapeutic strategies for …

… NLRP3 inflammasome has been shown to play a key role in … inflammasome inhibitors in the
treatment of COVID-19 has … and hydroxychloroquine on inflammasome. Studies indicate that …

… , activates NLRP3 inflammasome and consequently … COVID-19 by inhibiting some key
inflammation-associated transcription factors such as NF-κB and impeding NLRP3 inflammasome. …

… discusses reported inhibitors of the NLRP3 inflammasome in … ) inhibitors in the treatment of
SARS-CoV-2 (COVID-19). To … or novel agents) inhibitors of the NLRP3 inflammasome in pre-…

… inflammasome inhibitor MCC950 before SARS-CoV-2 infection in mice as indicated. …
importance in COVID-19 disease progression. Specific NLRP3 inflammasome inhibitor MCC950 …

… previous studies have shown that inhibition of the NLRP3 inflammasome lowers the levels of
… mice (124), suggesting that inflammasome inhibition may be beneficial to control the effects …

… indirect inflammasome activation and the critical role of inflammasomes in severe COVID-19. …
inflammation and coagulation in COVID-19 suggests that inhibiting it could be beneficial. …

… chemokines after inflammasome inhibition reversed the immune-pathological state of the
lungs, measured by scoring lung histopathology (Fig. 4h). Inflammasome inhibition reduced …

… The first clinical study for a NLRP3 inflammasome inhibitor (Tranilast) to treat COVID-19 is
ongoing and registered in the Chinese clinical trial registry (45). Other studies are still in a pre-…